Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study

Απλή σελίδα τεκμηρίου
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorKardamakis, D.en
dc.contributor.authorBamias, A.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorSakantamis, A.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:37:30Z
dc.date.available2015-11-24T19:37:30Z
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24038
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapy/pathology/*radiotherapy/surgeryen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCamptothecin/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectChemotherapy, Adjuvant/adverse effectsen
dc.subjectFeasibility Studiesen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosage/adverse effectsen
dc.subjectHumansen
dc.subjectLeucovorin/administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectRadiotherapy, Adjuvant/adverse effectsen
dc.subjectRectal Neoplasms/*drug therapy/pathology/*radiotherapy/surgeryen
dc.titleAdjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility studyen
heal.abstractBACKGROUND: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied the toxicity profile of postoperatively administered CPT-11 plus leucovorin (LV)-modulated 5FU and radiotherapy in patients with rectal cancer. PATIENTS AND METHODS: Thirty-seven patients with Dukes' B2 and C rectal adenocarcinoma were treated with CPT-11, 80 mg/m2 ii.v. over 90 minutes followed by LV 200 mg/m2 over 2 hours and 5FU 450 mg/m2 i.v.-bolus weekly for 4 weeks followed by a 2-week rest period. One cycle included 4 infusions. The first cycle of chemotherapy was followed by pelvic radiation to a total dose of 45 Gy to the whole pelvis and a boost of 5 Gy to the tumor bed. 5FU was administered daily as a rapid infusion during the first 3 as well as the last 3 days of radiotherapy. CPT-11 plus LV-modulated 5FU was continued for a total of 6 cycles or consent withdrawal. RESULTS: The main toxicity was reversible diarrhea (grade 3 and 4) in 9 (26%) patients during chemotherapy and in 3 (9%) patients during chemoradiotherapy. Furthermore, grade 3 leucopenia in 2 (6%) and 1 (3%) patient was observed during chemotherapy and chemoradiotherapy, respectively. CONCLUSION: This study provides evidence that adjuvant therapy using CPT-11 plus LV modulated 5FU and radiotherapy can be used in patients with rectal cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12820441-
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ